References/Bibliography
- Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Medicine 2007; 2: 373 – 399
- Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Medicine Reviews 2004; 8: 355-366
- Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 2010; 31: 371 – 381
- Narcolepsy UK Website http://www.narcolepsy.org.uk/AboutNarcolepsy/Whatisnarcolepsy.aspx#.T7qoR3nOxc4
- Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol. 2006 March; 61(3): 243–245.
- Dauvilliers Y., Arnulf I, Mignot E. Narcolepsy with Cataplexy. Lancet (Seminar) 2007; 369: 499 – 511
- Robinson DM, Keating GM. Sodium oxybate in the management of narcolepsy. CNS Drugs 2007.
- Watson CJ, et al. Sleep 2008;31:453-644) Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Medicine 2007; 2: 373 – 399
- Fujiki N, Ripley B, Yoshida Y, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003;6(8):953–9
- Benca RM. Narcolepsy and excessive daytime sleepiness: Diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry 2007;68[suppl 13]:5–83.
- http://trihealth.adam.com/content.aspx?productId=10&pid=10&gid=000098#adamHeading_7
- http://www.narcolepsynetwork.org/about-narcolepsy/faq/
- J Clin Psychiatry 2007;68[suppl 13]:16–192.
- Canadian Medical Association 2006. CMA Driver's Guide. Determining Medical Fitness to Operate Motor Vehicles 7th edition. Accessed May 22, 2012 from http://www.cma.ca/determining-fitness-to-drive#copyright
- Lexi-Drugs. Lexi-Comp Online 2012.
- Canadian Pharmacists’ Association 2012. e-CPS Online.
- Wang Y.G et al. Safety Overview of Postmarketing and Clinical Experience of Sodium Oxybate (Xyrem): Abuse, Misuse, Dependence, and Diversion. Journal of Clinical Sleep Medicine 2009; 5(4): 365 – 380
- Xyrem International Study Group. Evidence supporting the use of sodium oxybate for the treatment of narcolepsy: a double-blind, placebo-controlled study in 228 patients. Sleep Medicine 6 (2005): 415 – 421
- Black J. Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; jul1; 29(7): 939 – 46
- Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep 2006 Sep 1; 29(9): 1189 - 94
- Nishino S. Okuro K. Emerging treatments for narcolepsy and its related disorders. Expert Opin. Emerging Drugs. (2010): 15(1)
- http://www.xyrem.com/healthcare-professionals/direct-your-patients
- http://www.xyrem.com/healthcare-professionals/dosing-and-administration
- Fuller DE et al. The Xyrem Risk Management Program. Drug Safety 2004; 27(5): 293 – 306
- Valeant Canada Ltd. Xyrem (sodium oxybate) Product Monograph. Sept 2009. Accessed June 3, 2012 from http://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng